Published in Blood Weekly, October 4th, 2001
The new policy became effective September 1, 2001. The decision is significant because more than 10% of all patients with cirrhosis will develop HCC. This is particularly true with hepatitis B and C patients, who make up the single largest group of liver transplant patients (40%), and with rates of hepatitis on the rise in the United States, more patients are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.